A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.
Patients who took the once-weekly injection, eloralintide, lost as much as 20% of their body weight after 48 weeks, according to researchBloomberg Terminal published Thursday in The Lancet. The weight loss hadn’t plateaued by the end of the study, suggesting it could continue with longer treatment.